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Abstract
Transcriptional silencing of tumor suppressor genes and other cancer-related genes induced by
promoter CpG island hypermethylation is an important epigenetic mechanism of
hepatocarcinogenesis. Previous studies have established methylation profiles of hepatocellular
carcinomas (HCCs) and demonstrated that methylation of several candidate genes in resected
tissues may be associated with time to recurrence. The goals of our study were to test whether
specific promoter methylation and mRNA levels of candidate genes, as well as global changes in
DNA methylation, can be linked with time to recurrence and clinicopathological variables in a
homogenous study group of HCC patients. Forty-three tumorous and 45 non-tumorous liver tissue
samples from the surgical margin were obtained from HCV-positive, HBV-negative HCC patients
who underwent tumor resection surgery and who were monitored for tumor recurrence thereafter
(median follow-up time: 16 months (range, 0 – 79 months)). Methylation-specific PCR was used
to assess the promoter methylation status of P16(INK4a), SOCS-1, RASSF1A, APC, GSTP1, RIZ1,
and MGMT genes, while the level of LINE-1 methylation was used as marker of global DNA
methylation levels. Methylation frequencies in P16(INK4a), RASSF1A, APC, GSTP1, and RIZ1
genes were significantly greater in tumorous versus non-tumorous tissues. Methylation of RIZ1 in
non-tumorous tissues was significantly associated with time to recurrence. Additionally, genomic
DNA was significantly more hypomethylated in tumorous tissues, and this change was associated
with shorter recurrence, but not with clinicopathological features. In conclusion, this study
supports the role of aberrant methylation in the pathobiology of HCV-positive HCCs. The finding
that RIZ1 methylation and increased levels of LINE-1 hypomethylation in non-tumorous tissues
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are associated with time to recurrence underscores the importance of assessing the epigenetic state
of the liver remnant.
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1. Introduction
Hepatocellular carcinoma (HCC) is the fifth most common and the third most fatal
malignancy worldwide [1]. While the incidence of many cancers is declining, HCC
incidence continues on the upward trajectory over the last three decades in many countries,
including the U.S. and Japan. Over 80% of hepatocellular carcinoma cases are attributable to
four major causes: infection with hepatitis C (HCV) or B (HBV) viruses, chronic alcohol
consumption, and/or exposure to aflatoxin B1 [2]. Profound geographic variation in HCC
incidence and etiology is well known; the highest density of cases occur in Southeast Asia
and are associated primarily with chronic HBV (China), or HCV (Japan) infection [3,4]. It is
widely believed that the continuous epidemic of HCV largely accounts for the observed
increase in HCC incidence [4,6]. Clinical management of HCC is challenging due both to
the lack of diagnostic and prognostic biomarkers and resistance of HCC to chemotherapy
and radiation treatment. Tumor resection and ablation are common clinical choices;
however, survival is poor, with a 5-year recurrence rate of over 75% and a 5-year survival as
low as 50% [7,8]. Though clinicopathological features are useful in identifying patients who
are at-risk for recurrence, molecular predictors have also been proposed [9,10].
In liver and other tissues, gene-specific promoter hypermethylation is increasingly
recognized as a common epigenetic event throughout all stages of carcinogenesis [11–13].
Several studies have shown aberrant hypermethylation of P16(INK4a), RASSF1A, SOCS-1,
GSTP1, APC, RIZ1, and MGMT in HCC [14–19]. Furthermore, methylation profiling of
HCC has been successful in characterizing some of the antecedent methylation changes of
specific genes in cancer initiation and promotion, aberrations that have been shown to
accompany distinct, sequential histopathologic steps during hepatocarcinogenesis
[17,20,21]. This has been crucial in providing evidence for field cancerization of HCC, the
notion that HCC recurrences represent formations of additional field tumors that develop
from patches of genetically and epigenetically dysregulated preneoplastic cells in the
diseased liver [22,23]. In addition, it has been suggested that the methylation status of many
of these genes can be predictive of recurrence-free and overall survival, albeit there is some
inconsistency between the studies for individual genes as predictive biomarkers. Even in
relatively small study groups (60 pairs of tumorous and adjacent non-tumorous tissues or
fewer), the methylation status of GSTP1, CDH1, P16(INK4a), CRABP1, and SYK in
tumorous tissues corresponds to shortened overall survival [17,24,25], while specific
promoter hypermethylation of MGMT in tumorous tissues and RIZ1 in the non-tumorous
tissues have been reported as associated with time to recurrence [18].
Underpinning the complex and aberrant epigenetic milieu of hepatocarcinogenesis, gene-
specific hypermethylation is often accompanied by global genomic hypomethylation, an
epigenetic event associated with oncogene activation and overall genomic instability during
carcinogenesis [26]. Though several studies offer conflicting reports of the relationship
between global DNA hypomethylation and hypermethylation of specific genes [25,27], it
has been demonstrated that global DNA hypomethylation in tumorous tissues is inversely
correlated with overall patient survival in studies consisting of 60 [26] or 85 samples [28].
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However, most of the previous reports that have examined epigenetic changes in HCC
consisted of patient study groups that were heterogeneous with respect to the underlying
disease etiology. Additionally, epigenetic studies of HCC only seldom include simultaneous
analyses of both methylation status and gene expression levels. Thus, characterization of
epigenetic and gene expression changes specific to HCV-positive/HBV-negative disease
etiology and identification of genes whose promoter methylation status might be predictive
of time to recurrence were paramount goals of this study. We determined both global DNA
methylation levels and gene-specific methylation status in tumorous and adjacent non-
tumorous tissues in an etiologically and geographically distinct study group of HCC
patients, compared the association between promoter methylation and gene expression, and
analyzed the relationship between these epigenetic aberrations and both clinicopathological
variables and time to recurrence.
2. Materials and Methods
2.1 Patient study group and sample collection
The study group consisted of 49 HCV-positive, HBV-negative subjects with primary HCCs
who underwent curative resection surgery at the University of Yamanashi Hospital
(Yamanashi Prefecture, Japan) between 2000 and 2007 (mean age = 66.2 ± 8.1 years; 37
males and 12 females). A summary of the clinicopathological characteristics of the study
group can be found in Tsuchiya et al., 2010 [29]. After surgery, patients returned monthly to
the clinic for follow-up tests. Ultrasounds or computed tomography scans of the liver were
performed every 3 or 6 months, respectively, to determine the time to recurrence. Follow-up
continued until a detectable recurrence, patient death, or the end of the study in July 2008
(median follow-up: 16 months (range, 0 – 79 months)). Written, informed consent was
obtained in accordance with the Institutional Board on Ethics for Human Science at the
University of Yamanashi. Following removal of the tumor(s), fresh tissue samples were
collected from the tumorous and the non-tumorous surgical margin, frozen in liquid nitrogen
and stored at −80º C until laboratory processing. Due to insufficient tissue quantities from
several of the patients, 43 tumorous and 45 non-tumorous tissue samples were used in the
present study, representing 39 paired tissue samples from the same patients. DNA samples
from 10 non-transplant grade human livers (free from liver disease according to the
pathology reports) were kindly provided by Drs. Stephen Ferguson and Jonathan Jackson
(LifeTechnologies, Durham, NC) and used as controls.
2.2 DNAisolation and sodium bisulfite conversion
DNA was isolated from frozen tissue samples by a procedure that was slightly modified
from one reported previously [30]. Briefly, tissue was mechanically lysed with a Retsch
Tissue Lyser (Qiagen, Valencia, CA) then subjected to a Cell Lysis Solution (5 Prime Inc.,
Gaithersburg, MD) and proteinase K (Roche Diagnostics, Indianapolis, IN) digestion,
followed by incubation with Protein Precipitation Solution (5 Prime Inc., Gaithersburg,
MD). Nucleic acids were precipitated with 100% isopropanol and RNAs were digested with
Ribonuclease A (Sigma, St. Louis, MO). An additional proteinase K digestion and protein
precipitation, followed by DNA precipitation with 100% isopropanol, were performed. DNA
was resuspended and stored in ddH2O at −80º C until use. For bisulfite conversion, 2 μg of
sample liver DNAs, along with control methylated and unmethylated human DNA (Zymo
Research, Orange, CA) were treated with the EZ DNA Methylation-Gold Kit (Zymo
Research).
2.3 Methylation-specific Polymerase Chain Reaction (MSP)
Methylated and unmethylated primer sequences for P16(INK4a), SOCS-1, RASSF1A, APC,
GSTP1, RIZ1 and MGMT genes are shown in Supplemental Table 1 [refs. 14–18,31]. Four-
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hundred ng of bisulfite-converted DNA (10 μL), 50 pmol forward and reverse primers (5 μL
each, Nucleic Acids Core Facility, UNC-Chapel Hill), 5 μL ddH2O, and 25 μL 2X Amplitaq
Gold PCR Master Mix (Applied Biosystems, Foster City, CA), for a final reaction volume of
50 μL, were subjected to MSP under the following conditions: 95ºC for 10 min., 35 cycles
of 45 s at 95ºC, 60 s at the annealing temperature specific for each primer set, 60 s at 72ºC,
and a final 10 min. extension at 72ºC. Each sample was PCR-amplified using both
methylation-specific and unmethylation-specific primers. The final PCR products were
vacuum-concentrated to 20 μL and run on a 1.75% agarose gel. Ethidium bromide stain was
used for DNA visualization and Kodak 1D Image Analysis Software (Sigma, St. Louis, MO)
was used for image processing. The presence of a band at the expected fragment length was
scored as positive for methylation; absence was scored as negative (see Supplemental Figure
1A for an example).
2.4 Combined bisulfite restriction analysis (COBRA) of LINE-1
The levels of global DNA methylation was assessed by COBRA of long interspersed nuclear
elements (LINEs) as previously described by Yang et al. [32]. Briefly, a 413 bp region of
LINE-1 was amplified by PCR. The PCR product was aliquoted into two samples; half was
digested with HinFI restriction endonuclease (New England Biolabs, Ipswich, MA) and half
was left undigested. Each treatment was run in tandem on a 1.75% agarose gel and
visualized as detailed above. Because HinFI will only digest repetitive elements that were
originally methylated, a higher ratio of 413 bp band intensities between the digested and
undigested treatments indicates more globally hypomethylated genomic DNA in a tissue
sample (see Supplemental Figure 1B for an example). Agarose gels were photographed
using AlphaDigiDoc Pro System (Alpha Innotech, San Leandro, CA). The signal intensity of
undigested and digested LINE-1 PCR fragments from agarose gel images were quantified
using ImageQuant 5.1 Software (Molecular Dynamics, Sunnyvale, CA) and ratio of the
signal intensity of digested to undigested DNA fragments were used to determined level of
methylation.
2.5 Gene expression data
As part of a companion study [29], gene expression data from microarrays were available
for most of the tumorous (41/43) and non-tumorous (43/45) samples. Raw microarray data
was archived in Gene Expression Omnibus (GSE17856) and is available to the public.
Levels of mRNA were compared to methylation status of the seven genes investigated and
analyses were performed to determine the relationships between gene expression and time to
recurrence and clinicopathologic variables. Gene expression data was further used to guide
the search of new candidate genes that were potentially regulated by promoter
hypermethylation.
2.6 Statistical Analyses
Most of the statistical tests were performed separately within sub-groups consisting of the
tumorous and non-tumorous samples. McNemar’s, chi-square, Fisher’s exact tests and both
paired and unpaired Student’s t-test were used to compare methylation frequencies between
tumorous and non-tumorous samples, to determine associations between the methylation
status of each gene and clinicopathological variables, to examine differences in gene
expression according to methylation status, and to compare LINE-1 methylation levels
between samples. Univariate and multivariate Cox proportional hazards models were used to
investigate relationships between promoter methylation status, gene expression, and
clinicopathological data with time to recurrence with JMP software (version 6, SAS Institute
Inc., Cary, NC). Kaplan-Meier recurrence-free survival curves were generated and Mantel-
Cox log-rank tests were performed to assess the association between time to recurrence and
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gene-specific status or global DNA methylation levels using software from GraphPad Prism
(v. 5, San Diego, CA). A p-value <0.05 was considered statistically significant.
3. Results
3.1 Clinicopathological characteristics of the patient study group
In all of the statistical analyses performed in this study, the full study group (49 subjects)
was divided into patients for which DNA and gene expression data from HCC samples
(n=43), or non-tumorous samples (n=45) were available. There were 39 paired samples. The
patients in each sub-group did not differ significantly with respect to any of the
clinicopathological variables (data not shown). As a first step to consider the relationship
between the typical clinicopathological variables of HCC resection patients, including
demographic characteristics, tumor information, laboratory results, and the time to
recurrence, univariate Cox proportional hazards analyses were performed. In both sub-
groups, tumor number, tumor diameter, and tumor stage were significantly associated with
an earlier recurrence (Supplemental Table 2).
3.2 Gene-specific promoter methylation analysis in tumorous and non-tumorous tissues
Aberrant promoter methylation of P16(INK4a), SOCS-1, RASSF1A, APC, GSTP1, RIZ1, and
MGMT is commonly reported in epigenetic studies of HCC [14–19]. Here, we examined the
methylation profile of these 7 genes, which are associated with a number of dysregulated
pathways during carcinogenesis, in both tumorous and non-tumorous samples from HCV-
positive HCC patients (Table 1). All of these genes were almost entirely unmethylated in the
DNA from control human livers; however, the frequencies of methylation of all genes,
except MGMT, were significantly higher (p<0.05, Fisher’s exact test) in tumorous samples
as compared to control liver. In non-tumorous samples, the methylation frequencies of only
SOCS-1 and RASSF1A were significantly higher than those in controls.
We applied McNemar’s version of the chi-square test to compare the methylation
frequencies between the 39 pairs of tumorous and non-tumorous tissue samples. The
frequencies of methylation of p16(INK4a), RASSF1A, APC, GSTP1, and RIZ1 were
significantly higher in tumorous as compared to non-tumorous tissues, while the methylation
frequency of MGMT showed an opposite trend, and SOCS-1 exhibited an equally high
methylation frequency in both sub-groups (Table 1).
In addition to identifying differences in gene-specific frequencies of methylation between
tumorous and non-tumorous tissues, we were interested in investigating the significance of
the multiplicity of methylated genes in the pathogenesis of HCC. Figure 1 shows the
distribution of the number of samples with multiple methylated genes in control, non-
tumorous and tumorous tissues. There was a statistically significant increase in the number
of methylated genes as pathology progressed from normal to neoplastic, as the average
number of methylated genes (± SD) in control, non-tumorous, and tumorous samples was
0.1 (± 0.3), 2.2 (±1.0), and 4.9 (±1.0), respectively (p<0.001, unpaired t-tests).
3.3 Analysis of methylation accordance between tumorous and non-tumorous tissues
The nonzero number of non-tumorous samples for which promoter methylation was detected
in each gene examined and the significantly higher methylation frequencies of SOCS-1 and
RASSF1A in non-tumorous tissues relative to control liver provide evidence for field
cancerization [18,23] within the preneoplastic tissue adjacent to HCC. To further explore
this concept, we determined the accordance between methylation status in tumorous and
non-tumorous tissue from the same patient for each gene. To characterize a tumor as
monoclonal or polyclonal in origin [33], a comparison of the methylation status between
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paired tumorous and non-tumorous samples was performed. There are four possible
combinations of methylation status for each tissue pair: the gene is methylated in both the
non-tumorous tissue and the corresponding tumorous tissue (T+/NT+), the gene is
methylated in the tumorous, but not in non-tumorous tissue (T+/NT−), the gene is
methylated in neither tissue (T−/NT−), or the gene is methylated in the non-tumorous, but
not the tumorous tissue (T−/NT+). The first three combinations can be identified as
accordant and have been suggested to be of monoclonal origin [18]. When comparing each
sample pair type by each specific gene (Table 2), the majority of tissues were either T+/NT−
(avg. 42%) or T+/NT+ (avg. 28%). However, at least one sample pair was discordant (that
is, T−/NT+) for methylation in all genes except RASSF1A and APC, indicating that these
tumors were polyclonally derived and providing support for multicentric HCC
tumorigenesis, as described by others [34].
Additionally, we analyzed accordance between the methylation status in tumorous and
corresponding non-tumorous tissues for all 7 genes and found that 28 (72%) of the pairs
were accordant for all genes. Of the 11 pairs that were not accordant for all genes, 10 were
discordant for only one gene (Supplemental Figure 2). Moreover, the 11 discordant pairs
were obtained from patients who experienced an average time to recurrence that was longer
than those patients harboring accordant tumorous/non-tumorous tissue pairs (29.3 months
versus 20.9 months), though this relationship was not statistically significant (p=0.20, data
not shown).
3.4 Association between promoter methylation status, time to recurrence, and
clinicopathological variables
To investigate the association between gene methylation status and time to recurrence, we
performed univariate Cox proportional hazards analyses for all genes in both the tumorous
and non-tumorous sub-groups. We observed that only hypermethylation of RIZ1 in non-
tumorous tissues was significantly associated with a higher risk for earlier recurrence
(HR=2.29; 95% CI=1.22–3.83; p=0.01, Table 1). However, this relationship was not
significant in the multivariate analysis when other significant univariate clinicopathological
predictors (tumor diameter, tumor number, and tumor stage) were included (data not
shown). Figure 2 shows Kaplan-Meier recurrence-free survival curves according to the
methylation status of RIZ1 and P16(INK4a), a representative non-significant gene, in
tumorous and non-tumorous tissues. Despite the prominent shift in the number of
methylated genes as pathology progressed from control to tumorous tissue (Figure 1),
univariate Cox proportional hazards analyses revealed that the number of methylated genes
per tumorous sample did not dispose the patient to a higher risk for earlier recurrence (data
not shown). In addition, we examined the relationship between gene methylation status and
clinicopathological variables (Supplemental Table 3). Only a few significant (p<0.05)
relationships were found.
3.5 Global DNA methylation analysis in tumorous and non-tumorous tissues
Though promoter hypermethylation of specific genes is a common epigenetic event in
hepatocarcinogenesis, this specific aberration is often concurrent with global DNA
hypomethylation [27]. Therefore, in addition to examining gene-specific hypermethylation,
global DNA hypomethylation in tumorous and non-tumorous tissues was assessed by
analyzing the level of LINE-1 methylation as a marker for global DNA methylation levels.
LINE-1 was significantly (p<0.001) more hypomethylated in tumorous tissues as compared
to non-tumorous tissues (Figure 3A). When patients were divided into those with an earlier
recurrence (<1 year) or later recurrence (>1 year), the level of hypomethylation in the
tumorous samples was significantly higher in patients with earlier recurrences. The same
was true when assigning 2 years as the cutoff between early and late recurrence (Figure 3B).
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When patients with HCV-associated HCC were sub-divided into two groups based on the
median value of LINE-1 hypomethylation in non-tumorous tissues, a nearly significant
difference in time to recurrence outcome between the groups was observed; patients with
higher hypomethylation experienced earlier recurrences (p=0.06, Figure 3C). The level of
LINE-1 hypomethylation in tumorous tissues was also significantly inversely correlated
with ALT levels (data not shown). In non-tumorous tissues, LINE-1 hypomethylation was
significantly directly correlated with tumor diameter (r2 = 0.11, p = 0.03, data not shown).
No other correlations with clinicopathological variables were observed (Supplemental Table
4). Univariate Cox proportional hazards analyses revealed that the level of global DNA
hypomethylation in either tissue type was not significantly related to time to recurrence.
There was also no association between the degree of LINE-1 hypomethylation and the
methylation status of any of the 7 genes, or the number of genes methylated in either the
tumorous or non-tumorous sub-group (Supplemental Table 4).
3.6 Variable concordance between gene expression and promoter methylation status in
tumorous and non-tumorous tissues
Though the functional consequence of promoter methylation is frequently presumed to be a
reduction in gene expression, this relationship is only infrequently evaluated in clinical
studies. Using microarray data collected from the same tumorous and non-tumorous
samples, we compared the promoter methylation status of the 7 candidate genes with their
mRNA levels. There were significant differences in the expression level for 6 genes between
tumorous and non-tumorous tissues (Figure 4, Supplemental Table 5). When tumorous and
non-tumorous subgroups were pooled, corresponding gene expression levels were
significantly lower in samples with RIZ1 methylation (p<0.01) and GSTP1 methylation
(p=0.01). Interestingly, P16 expression was significantly higher in methylated versus
unmethylated tissues, a relationship that was also true when analyzing only tumorous
tissues. Significant concordance between lower gene expression and methylation of MGMT
was also observed in the non-tumorous sub-group (Supplemental Table 5). The univariate
Cox proportional hazards models analyses of the association between gene expression and
time to recurrence showed that only one probe for the SOCS-1 gene was significant, and
only in non-tumorous tissues (HR=8.09; 95% CI=1.11–52.5; p=0.04). For this same probe,
gene expression in methylated tissues was marginally significantly lower (p=0.06) in pooled
tumorous and non-tumorous tissues (Supplemental Table 5).
We previously reported a strongly predictive time to recurrence signature based on the gene
expression data of 91 genes in non-tumorous tissues from patients with a late (>1 year)
recurrence [29]. This signature was independently prognostic in the multivariate Cox
proportional hazards analysis that included both tumor diameter and the number of tumors.
To examine whether differences in expression of these biomarker genes may be linked to
promoter methylation, we chose the top 20 genes with the most significant Cox scores with
regards to time to recurrence for methylation analysis (Supplemental Figure 3). Of these, 9
(45%) had putative CpG islands in the promoter region, and methylated DNA- and
unmethylated DNA-specific primers were designed. We screened 8 paired tumorous and
non-tumorous samples (4 from patients with <1 year recurrence and 4 from patients with >1
year recurrence) for CpG region methylation in these 9 genes and found them to be
uniformly unmethylated in both tissue types (data not shown).
4. Discussion
Gene-specific promoter hypermethylation and global DNA hypomethylation are common
epigenetic aberrations found in human liver tumors; however, answers to questions
regarding the epigenetic changes specific to the underlying disease etiology remain elusive.
Additionally, though the functional consequence of promoter hypermethylation is
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transcriptional silencing of the associated gene, this assumption often goes untested, as few
have concurrently investigated both methylation and gene expression. In this study, we
examined both gene-specific changes in promoter methylation and gene expression levels
and global DNA methylation levels in tumorous and non-tumorous surgical margin tissues,
and investigated the relationship between the epigenetic changes and both
clinicopathological variables and time to recurrence. Herein, we report significant
differences in both gene-specific hypermethylation and global DNA hypomethylation levels
between tumorous and non-tumorous tissues and confirm the utility of RIZ1
hypermethylation in non-tumorous tissues as a predictive biomarker of earlier recurrence
following tumor resection.
We examined gene-specific methylation of selected genes, including P16(INK4a), SOCS-1,
RASSF1A, APC, GSTP1, RIZ1 and MGMT based on their relevance in several cancer
pathways (e.g., cell cycle regulation, inhibition of the Ras pathway, xenobiotic metabolism
and DNA repair) that are frequently disturbed in HCC [14–19]. Consistent with other
studies, we observed higher frequencies of promoter methylation in tumorous versus non-
tumorous tissues for P16(INK4a), RASSF1A, APC, GSTP1, and RIZ1. The high frequency of
methylation in tumorous tissues for all genes, except MGMT, as well as the high average
number of genes methylated per sample (4.9), suggest that HCV-associated HCC is
characterized by concordant methylation of multiple genes, epigenetic events which might
signify the emergence of the CpG island methylator phenotype, an important feature of
many human neoplasms [35]. Interestingly, however, both SOCS-1 and RASSF1A genes
were methylated at high frequencies in non-tumorous tissues, and MGMT was significantly
more methylated in non-tumorous tissues, indicating that epigenetic aberrations in
surrounding non-neoplastic tissues are important events in HCC tumorigenesis [20,36].
Indeed, all of the genes examined were methylated in at least two of the non-tumorous
samples, and the average number of methylated genes in non-tumorous samples was 2.2.
Similarly, other researchers have demonstrated that promoter hypermethylation is far more
frequent in non-tumorous HCV-positive liver as compared to non-tumorous HCV-negative
liver [20]. Thus, the aberrant gene-specific methylation profile in this etiologically distinct
subclass of HCC reveals the importance of epigenetic changes in virus-associated
hepatocarcinogenesis. In addition, the high methylation frequencies observed in the surgical
margin of non-tumorous liver tissue suggest epigenetic evidence for field cancerization in
HCC and may be related to the rapidity of HCC recurrence following resection.
A major focus of our study was to elucidate the relationship between changes in global and/
or gene-specific DNA methylation and time to recurrence. The potential relevance of using
methylation status as a predictor for overall or time to recurrence has been explored by
several investigators, and with encouraging results. Specifically, hypermethylation of
GSTP1 and P16 was previously reported as significantly associated with reduced overall
survival [17,24], while MGMT hypermethylation in tumorous tissues and RIZ1
hypermethylation in non-tumorous tissues were significantly related to earlier recurrence
[18]. The results of our study demonstrate that only methylation of RIZ1 in non-tumorous
tissues was associated with an increased risk for earlier recurrence. This serves as an
independent confirmation of the association between RIZ1 promoter hypermethylation and
shorter time to recurrence and is consistent with the finding that RIZ1 promoter
hypermethylation is an early event in hepatocarcinogenesis [36]. We optimistically posit that
RIZ1 hypermethylation tested in biopsy specimens may serve as a pre-clinical marker of
liver tumor development. We caution, however, that the number of genes examined in our
study was limited and perhaps the addition of other candidate genes may yield better
correlations between the number of methylated genes and time to recurrence. Importantly,
varying results between this study and others demonstrate how specific epigenetic changes
may be reflective of the distinct background liver disease of HCC.
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Several groups have recently demonstrated that global DNA hypomethylation accompanies
specific gene hypermethylation in HCC and contributes to carcinogenesis via protooncogene
activation and overall genomic instability [25–27]. We also show that genomic
hypomethylation, as assessed by LINE-1 methylation levels, occurs concomitantly with
specific gene hypermethylation in tumorous tissues. This finding corresponds to the results
of the study conducted by Kim et al. [27], demonstrating that hypermethylation of CpG
islands is related to the levels of LINE-1 hypomethylation in HCC.
Despite not finding a significant association between LINE-1 hypomethylation levels and
time to recurrence, we observed that the level of hypomethylation in tumorous tissues from
patients with earlier recurrences was significantly higher than that in subjects with later
recurrences in separate analyses that used either 1 year or 2 years as the cutoff for early
versus late recurrence. LINE-1 methylation levels in non-tumorous tissues did not differ
after dichotomization according to recurrence time, in agreement with the study conducted
by Calvisi et al. [26]. Interestingly, however, when time to recurrence was assessed after
binning non-tumorous tissues into below and above the median hypomethylation level, a
high level of hypomethylation in non-tumorous tissues increased the risk for earlier
recurrence with modest significance. This finding supports a role for global
hypomethylation in predisposing non-neoplastic surrounding tissue to the development of
secondary tumors.
Furthermore, our study combined epigenetic analyses with whole genome microarray data to
investigate molecular changes during hepatocarcinogenesis. Because it is well-recognized
that promoter hypermethylation may result in transcriptional repression, we aimed to
characterize the relationship between methylation of specific genes and corresponding
mRNA levels. We hypothesized that tissues in which gene promoters were methylated
would also show decreased expression. Even though we found significant differences in
gene expression between tumorous and non-tumorous tissues for all of the genes (except for
APC), RIZ1 and GSTP1 were the only genes whose expression was significantly lower in
methylated samples when examining both tumorous and non-tumorous samples together.
Counter-intuitively, expression of P16 was actually significantly higher in samples showing
P16 methylation. When analyzed separately in the tumorous sub-group, this relationship was
upheld. Additionally, MGMT expression was significantly lower in methylated samples in
the non-tumorous sub-group. RIZ1 hypermethylation was significantly associated with
reduced time to recurrence, and RIZ1 gene expression was lower in hypermethylated
samples, a relationship that has been demonstrated by others [37]. However, the univariate
Cox proportional hazards analyses showed that gene expression of RIZ1 and 5 of the other
genes analyzed was not associated with time to recurrence; only SOCS-1 expression in non-
tumorous samples was significantly associated with earlier recurrence.
The lack of the hypothesized correlation between promoter hypermethylation and reduced
gene expression in 5 of the 7 genes analyzed could be the result of examining only a limited
number of CpG sites in the gene promoters. Additionally, promoter hypermethylation is
only one of several epigenetic modifications affecting gene expression. Because mRNA
levels are quite dynamic, it is reasonable to suggest that other compensatory processes are
operating as cells attempt to reverse changes in expression due to promoter
hypermethylation. In the dysfunctional biological and molecular context of cancer, there
could be a myriad of mechanisms responsible for influencing gene expression, including
miRNA binding, chromatin and histone modifications, and larger chromosomal aberrations,
such as loss of heterozygosity. Finally, the over-sensitivity of methylation-specific PCR for
detecting methylation might partially explain the absence of the expected correlation
between promoter methylation status and gene expression.
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To further investigate the apparent lack of a direct relationship between methylation status
and gene expression, we attempted the converse approach, and selected candidates for
methylation analysis based on expression profiles of genes which were related to time to
recurrence. Except for GATA-4, all of the 9 genes identified with putative promoter CpG
islands had not previously been reported in the literature, and thus were novel targets for
methylation analyses. However, none of the genes were methylated in a subset of tumorous
and non-tumorous tissues, including GATA-4, which was previously reported to be
methylated in 58% of HCC cases [26]. Thus, overall, we conclude that there is a lack of
agreement between promoter methylation status and gene expression in a group of HCV-
positive HCC patients, and we reason that assessment of methylation status alone may not
be sufficient for explaining the downstream cascade of events leading to dysregulated gene
expression in HCV-associated hepatocarcinogenesis.
From a genome-wide perspective, then, it appears that gene expression signatures of time to
recurrence are more difficult to characterize, because a host of other mechanisms that affect
gene expression are operating, perhaps undetectably. By focusing within a smaller, more
gene-specific context, however, patterns of methylation appear to be more stable and robust
markers of the sequential accumulation of molecular aberrations along multistep
hepatocarcinogenesis. Biomarkers such as RIZ1 hypermethylation in non-tumorous tissues
may serve a more clinically useful role, as its association with earlier recurrence or as an
early event in tumorigenesis is reproducible between studies, even within distinct,
independent study groups [36,37].
In summary, we examined some of the epigenetic changes that sequentially accumulate
during HCV-related hepatocarcinogenesis and demonstrate the technical and practical
challenges of relating promoter methylation status to corresponding gene expression levels
and time to recurrence. Multiple genes in multiple pathways known to be dysregulated
during tumorigenesis were hypermethylated in both tumorous and non-tumorous tissues.
Additionally, changes in global DNA methylation levels were more pronounced in tumorous
tissues. Together, our epigenetic data establishes an aberrant methylation profile in an
etiologically distinct group of HCV-positive HCC cases. The finding that RIZ1 methylation
and increased levels of LINE-1 hypomethylation in non-tumorous tissues are associated with
time to recurrence underscores the importance of assessing the epigenetic state of the liver
remnant following tumor resection.
Novelty and impact
This study examined changes both in promoter hypermethylation of cancer-related genes
and gene expression levels in pairs of tumorous and non-tumorous tissues resected from
patients with HCV-associated hepatocellular carcinoma and analyzed associations
between these epigenetic changes and time to recurrence. These parallel analyses rarely
appear in reports of epigenetic changes in liver tumor biology and highlight the complex
relationship between epigenetic and genetic events in hepatocarcinogenesis.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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PCR polymerase chain reaction
P16(INK4a) Cyclin-dependent kinase inhibitor 2A
SOCS-1 suppressor of cytokine signaling 1
RASSF1A Ras association domain family 1A
APC adenomatous polyposis coli
GSTP1 glutathione S-transferase π 1
RIZ1 retinoblastoma protein-interacting zing-finger 1
MGMT O6-Methylguanine-DNA methyltransferase
LINE-1 long interspersed nuclear element-1
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Number of tumorous, non-tumorous and control DNA samples with 0 – 7 genes methylated.
Curves are drawn to distinguish the distribution of the number of genes methylated in
tumorous, non-tumorous, and control tissues. The average number of genes methylated (±
SD) was 4.9 (± 1.0) in tumorous tissues, 2.2 (± 1.0) in non-tumorous tissues and 0.1 (± 0.3)
in control samples. ** p<0.001, 2-tailed unpaired t-test.
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Kaplan-Meier recurrence-free survival curves based on promoter hypermethylation of tumor
suppressor genes. Curves are shown for RIZ1: (A), tumorous tissues, (B) non-tumorous
tissues; and p16: (C) tumorous tissues, (D) non-tumorous tissues. P-values from Log-Rank
(Mantel-Cox) tests are shown for differences in time to recurrence according to methylation
status.
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Analysis of LINE-1 hypomethylation levels in tumorous and non-tumorous tissues. (A), box
plot of average LINE-1 hypomethylation level according to tissue type. Medians,
interquartile ranges, minima and maxima are shown. **p<0.001, two-tailed, paired t-test.
(B), Differences in LINE-1 hypomethylation levels according to early or late recurrence.
Means + SEM are shown. *p<0.05, two-tailed, unpaired t-test. (C), Kaplan-Meier
recurrence-free survival curve and Log-Rank (Mantel-Cox) test of time to recurrence
according to high (above median) or low (below median) hypomethylation levels in non-
tumorous tissues.
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Clustering of gene expression data for seven tumor suppressor genes. Red = up-regulated;
blue = down-regulated; white = no change in expression, relative to the median gene
expression. Tumorous and non-tumorous samples are sorted based on time to recurrence,
with longer times to recurrence appearing on the right in each sub-group, corresponding to
darker green. Two different probes for the same gene are distinguished by (A) and (B).
*p<0.01; **p<0.001, from two-tailed, paired t-tests for significant differences in gene
expression between tumorous and non-tumorous samples.
Blue highlighting, gene expression significantly lower; and red highlighting, gene
expression significantly higher in samples showing promoter methylation of the same gene
when tumorous and non-tumorous samples were pooled (p<0.05, two-tailed, unpaired t-test).
§ Gene expression was significantly associated with risk for earlier recurrence for SOCS-1
(B) (p<0.05, Supplemental Table 5). Gene expression was lower in methylated versus
unmethylated samples for SOCS-1 (B) (p=0.06).
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Table 2
Methylation status in paired (n=39) tumorous and non-tumorous tissues from the same patient.
Gene T−/NT−(%) T−/NT+ (%) T+/NT−(%) T+/NT+ (%)
p16 7 (18%) 1 (3%) 25 (64%) 6 (15%)
SOCS-1 1 (3%) 3 (8%) 3 (8%) 32 (82%)
RASSF1A 0 (0%) 0 (0%) 12 (31%) 27 (69%)
APC 2 (5%) 0 (0%) 29 (74%) 8 (21%)
GSTP1 17 (44%) 1 (3%) 20 (51%) 1 (3%)
RIZ1 8 (21%) 1 (3%) 27 (69%) 3 (8%)
MGMT 33 (85%) 6 (15%) 0 (0%) 0 (0%)
Average % 25% 4% 42% 28%
T, tumorous; NT, non-tumorous; (−) indicates no promoter methylation and (+) indicates promoter methylation in tumorous or non-tumorous
tissues
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